Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: Results of a randomized phase II study

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 781-786

  Rosati, G ^a   Cordio, S ^b   Bordonaro, R ^c   Caputo, G ^b   Novello, G ^c   Reggiardo, G ^d   Manzione, L ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Garibaldi Nesima Hospital   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Medi Service   (Italy)

Author keywords

Advanced colorectal cancer; Capecitabine; Elderly; Irinotecan; Oxaliplatin

Indexed keywords

CAPECITABINE; CETUXIMAB; CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GERIATRIC PATIENT; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77951950980     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp359     Document Type: Article

References (30)

1. Gatta G, Faivre J, Capocaccia R et al. Survival of colorectal cancer patients in Europe during period 1978-1989: the EUROCARE Working Group. Eur J Cancer 1998; 34: 2176-2183.
2. Köhne CH, Folprecht G, Goldberg RM et al. Chemotherapy in elderly patients with colorectal cancer. Oncologist 2008; 13: 390-402.
3. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
4. Folprecht G, Seymour MT, Saltz L et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26: 1443-1451.
5. Clark DR, Raffin TA. Infectious complications of indwelling long-term central venous catheters. Chest 1990; 97: 966-972.
6. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-3675.
7. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine vs intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
8. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
9. Fiorentini G, Dentico P, Cantore M et al. Capecitabine plus irinotecan as second-line treatment for metastatic colorectal cancer in elderly patients: feasibility and safety results from a phase II study. J Clin Oncol 2005; 23: 289s (Abstr 3676).
10. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
11. Feliu J, Salud A, Escudero P et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94: 969-975.
12. Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005; 104: 282-289.
13. Twelves CJ, Butts CA, Cassidy J et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005; 5: 101-107.
14. Grothey A, Jordan K, Kellner O et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial. Eur J Cancer 2003; 1: 90s (Abstr 295).
15. Miller AB, Hoogstraten B, Staquet N. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
16. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
17. Sastre J, Marcuello E, Masutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. J Clin Oncol 2005; 23: 3545-3551.
18. Souglakos J, Pallis A, Kakolyris S et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 2005; 69: 384-390.
19. Botto HG, Botto ME. Combination of irinotecan and 5-fluorouracil, leucovorin in first and second line treatment in elderly patients with metastatic colo-rectal cancer. J Clin Oncol 2005; 24: 306s (Abstr 3743).
20. Kim JH, Oh DY, Kim YJ et al. Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J Korean Med Sci 2005; 20: 806-810.
21. Mattioli R, Massacesi C, Recchia F et al. High activity and reduced neurotoxicity of bi-fractioned oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16: 1147-1151.
22. Comandone A, Pochettino P, Bergnolo P et al. Capecitabine and oxaliplatin: a phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. J Clin Oncol 2005; 24: 291s (Abstr 3681).
23. Rosati G, Cordio S, Tucci A et al. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 2005; 69: 122-129.
24. Aparicio T, Desramé J, Lecomte T et al. Oxaliplatin-or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003; 89: 1439-1444.
25. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
26. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
27. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142.
28. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
29. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
30. Reinacher-Schick AC, Kubicka S, Freier W et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 2008; 26: 185s (Abstr 4030).